The price of innovation: new estimates of drug development costs

Boston Consulting Group, 1993. The Contribution of Pharmaceutical Companies: What’s at Stake for America. The Boston Consulting Group, Boston, MA, September 1993. US Congressional Budget Office, 1998. How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry. US Government Printing Office, Washington, DC, July 1998. Clarkson, 1977. Intangible Capital and Rates of Return, American Enterprise Institute, Washington, DC. CMR, 2000. Describing Dossiers: Characterising Clinical Dossiers for Global Registration. R&D Briefing 25, CMR International, Surrey, UK. DiMasi, 1991, Cost of innovation in the pharmaceutical industry, Journal of Health Economics, 10, 107, 10.1016/0167-6296(91)90001-4 DiMasi, 1995, Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry, PharmacoEconomics, 7, 152, 10.2165/00019053-199507020-00007 DiMasi, 1995, R&D costs, innovative output and firm size in the pharmaceutical industry, International Journal of the Economics of Business, 2, 201, 10.1080/758519309 DiMasi, 2000, New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms, Drug Information Journal, 34, 1169, 10.1177/009286150003400425 DiMasi, 2001, New drug development in the United States 1963–1999, Clinical Pharmacology & Therapeutics, 69, 286, 10.1067/mcp.2001.115132 DiMasi, 2001, Risks in new drug development: approval success rates for investigational drugs, Clinical Pharmacology & Therapeutics, 69, 297, 10.1067/mcp.2001.115446 F-D-C Reports, 1999. NDA Submissions are Shrinking in Size but Increasing in Complexity. The Pink Sheet 61, p. 28. Grabowski, 1990, A new look at the returns and risks to pharmaceutical R&D, Management Science, 36, 804, 10.1287/mnsc.36.7.804 Grabowski, 1994, Returns to R&D on new drug introductions in the 1980s, Journal of Health Economics, 13, 383, 10.1016/0167-6296(94)90010-8 Grabowski, 2000, The distribution of sales revenues from pharmaceutical innovation, PharmacoEconomics, 18, 21, 10.2165/00019053-200018001-00005 Grabowski, 2002, Returns on research and development for 1990s new drug introductions, PharmacoEconomics, 20, 11, 10.2165/00019053-200220003-00002 Guenther, G., 1999. Federal taxation of the drug industry from 1990 to 1996. Memorandum to Joint Economic Committee, US Congress, Congressional Research Service, 13 December 1999. Hansen, R.W., 1979. The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In: Chien, R.I. (Ed.), Issues in Pharmaceutical Economics. Lexington Books, Lexington, MA, pp. 151–187. Ibbotson Associates, 2001. Stocks, Bonds, Bills & Inflation: 2001 Yearbook, Ibbotson Associates, Chicago, Illinois. Kaitin, 2000, The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era, Drug Information Journal, 34, 1, 10.1177/009286150003400101 Kaitin, 2000, Measuring the pace of new drug development in the user fee era, Drug Information Journal, 34, 673, 10.1177/009286150003400303 Myers, S.C., Shyam-Sunder, L., 1996. Measuring pharmaceutical industry risk and the cost-of-capital. In: Helms, R.B. (Ed.), Competitive Strategies in the Pharmaceutical Industry. American Enterprise Institute, Washington, DC, pp. 208–237. Myers, S.C., Howe, C.D., 1997. A life-cycle financial model of pharmaceutical R&D. Working Paper, Program on the Pharmaceutical Industry. Massachusetts Institute of Technology, Cambridge, MA. National Institutes of Health, 2000. NIH Response to the Conference Report Request for a Plan to Ensure Taxpayers’ Interests are Protected: A Plan to Ensure Taxpayers’ Interests are Protected. National Institutes of Health, Rockville, MD, July 2001. US Congress, Office of Technology Assessment, 1993. Pharmaceutical R&D: Costs, Risks, and Rewards, OTA-H-522. US Government Printing Office, Washington, DC. Peck, 1997, Drug development: improving the process, Food and Drug Law Journal, 52, 163 Pharma Marketletter, 2001. Genomics may increase costs of NCE development, says Lehman Bros. Pharma Marketletter, vol. 28, 26 February 2001, pp. 24–25. PhRMA, 2000. Pharmaceutical Industry Profile 2000: Research for the Millennium, Pharmaceutical Research and Manufacturers of America, Washington, DC. PhRMA, 2001. Pharmaceutical Industry Profile 2001, Pharmaceutical Research and Manufacturers of America, Washington, DC. PJB Publications Ltd., 2000. Scrip’s 2000 Pharmaceutical Company League Tables, Richmond, Surrey, UK, 3 November 2000. Pollack, A., 2002. Despite Billions for Discoveries, Pipeline of Drugs is Far from Full. New York Times, 19 April 2002. Public Citizen, 2001. Rx R&D Myths: The Case Against the Drug Industry’s R&D Scare Card, Public Citizen, Congress Watch, July 2001. Reichert, 2000, New biopharmaceuticals in the US: trends in development and marketing approvals 1995–1999, Trends in Biotechnology, 18, 364, 10.1016/S0167-7799(00)01473-6 Scherer, F.M., 2000. The pharmaceutical industry. In: Newhouse, J.P. (Ed.), Handbook of Health Economics, vol. 1. Elsevier, Amsterdam, Chapter 25, pp. 1297–1336. Scherer, 2001, The link between gross profitability and pharmaceutical R&D spending, Health Affairs, 20, 216, 10.1377/hlthaff.20.5.216 Tollman, P., Guy, P., Altshuler, J., Flanagan, A., Steiner, M., 2001. A Revolution in R&D: The Impact of Genomics. The Boston Consulting Group, Boston, MA, June 2001. US Food and Drug Administration, Center for Drug Evaluation and Research, 1999. From Test Tube to Patient: Improving Health Through Human Drugs (special report). US Government Printing Office, Washington, DC, September 1999 (http://www.fda.gov/fdac/special/newdrug/ndd_toc.html).